Michael D Jain (Michael Jain)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 26

Top Venues

Blood advances

Blood

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

Moffitt Cancer Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Moffitt Cancer Center

United States

Assistant Member :: Dept. of BMT-CI

Publications

Michael D Jain, Melody Smith, Nirali N Shah
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy. Blood (2023)
Marion Subklewe, David M Cordas Dos Santos, Nathan H Parker, Veit L Bücklein, Michael Winkelmann, Khushali S Jhaveri, Lian Liu, Paul Trinkner, Sophie Günther, Philipp Karschnia, Viktoria Blumenberg, Christian Schmidt, Wolfgang Gerhard Kunz, Michael von Bergwelt-Baildon, Michael D Jain, Sebastian Theurich, Marion Subklewe
Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy. Cancer immunology research (2023)
Dae Hyun Lee, Abhishek Kumar, Turab Mohammed, Lauren C Peres, Melissa Alsina, Christina A Bachmeier, Brandon Blue, Jason Brayer, Sanjay Chandrasekhar, Ariel F Grajales-Cruz, Gabriel De Avila, Hany Elmariah, Rawan G Faramand, Ciara Louise Freeman, Michael D Jain, Sushmita Khadka, Farhad Khimani, Hien Liu, Taiga Nishihori, Laura B Oswald, Omar Castaneda Puglianini, Kenneth H Shain, Eric Smith, Rachid C Baz, Frederick L Locke, Guilherme Henrique Oliveira, Mohammed Alomar, Doris K Hansen
Cardiac Events After Standard of Care Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma. Blood advances (2023)
Christoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, Viktoria Blumenberg, Maria-Luisa Schubert, Uria Mor, Matthias A Fante, Sabine Schmidt, Eiko Hayase, Tomo Hayase, Roman Rohrbach, Chia-Chi Chang, Lauren McDaniel, Ivonne Flores, Rogier Gaiser, Matthias Edinger, Daniel Wolff, Martin Heidenreich, Paolo Strati, Ranjit Nair, Dai Chihara, Luis E Fayad, Sairah Ahmed, Swaminathan P Iyer, Raphael E Steiner, Preetesh Jain, Loretta J Nastoupil, Jason R Westin, Reetakshi Arora, Michael L Wang, Joel Turner, Meghan Menges, Melanie Hidalgo-Vargas, Kayla Reid, Peter Dreger, Anita Schmitt, Carsten Muller-Tidow, Frederick L Locke, Marco L Davila, Richard E Champlin, Christopher R Flowers, Elizabeth J Shpall, Hendrik Poeck, Sattva S Neelapu, Michael Schmitt, Marion Subklewe, Michael D Jain, Robert R Jenq, Eran Elinav
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nature medicine (2023)
Michael D Jain, David Bernard Miklos, Caron A Jacobson, John M Timmerman, Jennifer Sun, Jenny Nater, Xiang Fang, Ankit Patel, Madison Davis, Darren Heeke, Tan Trinh, Mike Mattie, Frank Neumann, Jenny J Kim, Christina To, Simone Filosto, Ran Reshef
Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Yucai Wang, Preetesh Jain, Frederick L Locke, Matthew J Maurer, Matthew J Frank, Javier L Muñoz, Saurabh Dahiya, Amer M Beitinjaneh, Miriam T Jacobs, Joseph P McGuirk, Julie M Vose, Andre H Goy, Charalambos Andreadis, Brian T Hill, Kathleen A Dorritie, Olalekan O Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent P Wang, Rahul Banerjee, David Bernard Miklos, Aaron P Rapoport, Lazaros Lekakis, Armin Ghobadi, Sattva S Neelapu, Yi Lin, Michael L Wang, Michael D Jain
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Marion Subklewe, Ariel Perez, Gloria Iacoboni, Viktoria Blumenberg, Veit L Bücklein, Simon Völkl, Olaf Penack, Omar Albanyan, Sophia Stock, Fabian Müller, Philipp Karschnia, Agnese Petrera, Kayla Reid, Rawan Faramand, Marco L Davila, Karnav Modi, Erin A Dean, Christina A Bachmeier, Michael von Bergwelt-Baildon, Frederick L Locke, Wolfgang Andreas Bethge, Lars Bullinger, Andreas Mackensen, Pere Barba, Michael D Jain, Marion Subklewe
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Science advances 9 (38) (2023)
Michael D Jain, Miriam T Jacobs, Feng Gao, Loretta J Nastoupil, Jay Y Spiegel, Yi Lin, Saurabh Dahiya, Matthew A Lunning, Lazaros J Lekakis, Patrick M Reagan, Olalekan O Oluwole, Joseph P McGuirk, Abhinav Deol, Alison Sehgal, Andre H Goy, Brian T Hill, Charalambos Andreadis, Javier L Muñoz, Julio C Chavez, N Nora Bennani, Aaron P Rapoport, Julie M Vose, David Bernard Miklos, Sattva S Neelapu, Frederick L Locke, Armin Ghobadi
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium. Blood advances (2023)
Erin A Dean, Gregory J Kimmel, Matthew J Frank, Ali Bukhari, Nasheed M Hossain, Michael D Jain, Saurabh Dahiya, David Bernard Miklos, Philipp M Altrock, Frederick L Locke
Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma. Blood advances (2023)
Marion Subklewe, Yucai Wang, Omar Albanyan, Javier Munoz, Pierre Sesques, Gloria Iacoboni, Lucia Lopez-Corral, Isabelle Ries, Veit L Bücklein, Razan Mohty, Martin Dreyling, Aliyah Baluch, Bijal D Shah, Frederick L Locke, Georg Hess, Pere Barba, Emmanuel Bachy, Yi Lin, Marion Subklewe, Michael D Jain
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. American journal of hematology (2023)
Michael D Jain, Bachisio Ziccheddu, Caroline A Coughlin, Rawan Faramand, Anthony J Griswold, Kayla M Reid, Meghan Menges, Yonghong Zhang, Ling Cen, Xuefeng Wang, Mohammad Hussaini, Carl Ola Landgren, Marco L Davila, Jonathan H Schatz, Frederick L Locke, Francesco Maura
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood 140 (5) (2022)
Abi Vijenthira, John Kuruvilla, Michael Crump, Michael D Jain, Anca Prica
Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Marion Subklewe, Ariel Perez, Gloria Iacoboni, Olaf Penack, Veit Bücklein, Liv Jentzsch, Dimitrios Mougiakakos, Grace Johnson, Brian Arciola, Cecilia Carpio, Viktoria Blumenberg, Eva Hoster, Lars Bullinger, Frederick L Locke, Michael von Bergwelt-Baildon, Andreas Mackensen, Wolfgang Bethge, Pere Barba, Michael D Jain, Marion Subklewe
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. Journal for immunotherapy of cancer 10 (5) (2022)
Nathalie Scholler, Regis Perbost, Frederick L Locke, Michael D Jain, Sarah Turcan, Corinne Danan, Edmund C Chang, Sattva S Neelapu, David Bernard Miklos, Caron A Jacobson, Lazaros J Lekakis, Yi Lin, Armin Ghobadi, Jenny J Kim, Justin Chou, Vicki Plaks, Zixing Wang, Allen Xue, Mike Mattie, John M Rossi, Adrian Bot, Jerome Galon
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nature medicine 28 (9) (2022)
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, Christelle M Colin-Leitzinger, Alexandria M Shrewsbury, Hitomi Hosoya, Rebecca Gonzalez, Christina Copponex, Krista H Kottra, Vanna Hovanky, Bita Sahaf, Sunita Patil, Aleksander Lazaryan, Michael D Jain, Aliyah Baluch, Olga Klinkova, Nelli Bejanyan, Rawan G Faramand, Hany Elmariah, Farhad Khimani, Marco L Davila, Asmita Mishra, Brandon Blue, Ariel F Grajales-Cruz, Omar Castaneda Puglianini, Hien Liu, Taiga Nishihori, Ciara Louise Freeman, Jason Brayer, Kenneth H Shain, Rachid Baz, Frederick L Locke, Melissa Alsina, Surbhi Sidana, Doris K Hansen
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood advances (2022)
Neeraj Y Saini, David M Swoboda, Uri Greenbaum, Junsheng Ma, Romil D Patel, Kartik Devashish, Kaberi Das, Mark R Tanner, Paolo Strati, Ranjit Nair, Luis Fayad, Sairah A Ahmed, Hun Ju Lee, Swaminathan P Iyer, Raphael E Steiner, Nitin Jain, Loretta Nastoupil, Sanam Loghavi, Guilin Tang, Roland L Bassett, Preetesh Jain, Michael L Wang, Jason R Westin, Michael R Green, David A Sallman, Eric Padron, Marco L Davila, Frederick L Locke, Richard E Champlin, Guillermo Garcia-Manero, Elizabeth J Shpall, Partow Kebriaei, Christopher R Flowers, Michael D Jain, Feng Wang, Andrew P Futreal, Nancy Gillis, Sattva S Neelapu, Koichi Takahashi
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood cancer discovery 3 (5) (2022)
Ariel Perez, Grace Johnson, Kedar Patel, Brian Arciola, Anthony Wood, Christina A Bachmeier, Julio C Chavez, Bijal D Shah, Farhad Khimani, Taiga Nishihori, Aleksander Lazaryan, Marco L Davila, Rahul Mhaskar, Frederick L Locke, Sameh Gaballa, Michael D Jain
Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood advances 6 (13) (2022)
Michael D Jain, Frederick L Locke
Seeing the Light: CAR T-cell Targeting of Lambda-restricted B-cell Lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (21) (2021)
Kai Rejeski, Ariel Perez Perez, Pierre Sesques, Eva Hoster, Carolina Susanna Berger, Liv Jentzsch, Dimitrios Mougiakakos, Lisa Frölich, Josephine Ackermann, Veit L Bücklein, Viktoria Blumenberg, Christian Schmidt, Laurent Jallades, Boris Fehse, Christoph Faul, Philipp Karschnia, Oliver Weigert, Martin Dreyling, Frederick L Locke, Michael von Bergwelt-Baildon, Andreas Mackensen, Wolfgang Andreas Bethge, Francis Ayuk, Emmanuel Bachy, Gilles Andre Salles, Michael D Jain, Marion Subklewe
CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. Blood (2021)
Matthew J Frank, Nasheed M Hossain, Ali Bukhari, Erin A Dean, Jay Y Spiegel, Gursharan K Claire, Ilan Kirsch, Allison P Jacob, Chelsea D Mullins, Lik Wee Lee, Katherine A Kong, Juliana K Craig, Crystal L Mackall, Aaron P Rapoport, Michael D Jain, Saurabh Dahiya, Frederick L Locke, David Bernard Miklos
Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (27) (2021)
Michael D Jain, Hua Zhao, Xuefeng Wang, Reginald Atkins, Meghan Menges, Kayla Reid, Kristen Spitler, Rawan Faramand, Christina A Bachmeier, Erin A Dean, Biwei Cao, Julio C Chavez, Bijal Shah, Aleksander Lazaryan, Taiga Nishihori, Mohammed Hussaini, Ricardo J Gonzalez, John E Mullinax, Paulo C Rodriguez, Jose R Conejo-Garcia, Claudio Anasetti, Marco L Davila, Frederick L Locke
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137 (19) (2021)
Michael D Jain, Jay Y Spiegel
Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes. EJHaem 3 (Suppl 1) (2021)
Aleksander Lazaryan, Stephanie J Lee, Mukta Arora, Jongphil Kim, Brian C Betts, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Hien Liu, Mohamed A Kharfan-Dabaja, Frederick L Locke, Rebecca Gonzalez, Michael D Jain, Marco L Davila, Lia Elena Perez, Asmita Mishra, Ariel Perez Perez, Karlie Balke, Ernesto Ayala, Leonel Ochoa, Omar Castaneda Puglianini, Rawan G Faramand, Melissa Alsina, Hany Elmariah, Michael Nieder, Hugo F Fernandez, Claudio Anasetti, Joseph Pidala
Phase 2 multicenter trial of ofatumumab and prednisone as initial therapy of chronic graft-vs-host disease. Blood advances (2021)
Michael D Jain, Ryan Lam, Zhihui Liu, Ryan J Stubbins, Amrit Kahlon, Roopesh Kansara, Rashmi Goswami, Atul Humar, Anca Prica, Laurie H Sehn, Graham W Slack, Michael Crump, Kerry J Savage, Anthea C Peters, John Kuruvilla
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder. British journal of haematology 189 (1) (2020)
Rawan Faramand, Michael D Jain, Verena Staedtke, Hiroshi Kotani, Renyuan Bai, Kayla Reid, Sae Bom Lee, Kristen Spitler, Xuefeng Wang, Biwei Cao, Javier Pinilla, Aleksander Lazaryan, Farhad Khimani, Bijal Shah, Julio C Chavez, Taiga Nishihori, Asmita Mishra, John E Mullinax, Ricardo Gonzalez, Mohammad Hussaini, Marian Dam, Brigett D Brandjes, Christina A Bachmeier, Claudio Anasetti, Frederick L Locke, Marco L Davila
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (18) (2020)
Hamza Hashmi, Christina Bachmeier, Julio C Chavez, Jinming Song, Mohammad Hussaini, Gabriel Krivenko, Taiga Nishihori, Hiroshi Kotani, Marco L Davila, Frederick L Locke, Michael D Jain
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. British journal of haematology 187 (2) (2019)

Michael D Jain.css-eqlu8i{font-size:small;padding-left:4px;} (Michael Jain)

Publication Activity (10 Years)

Top Topics

Top Venues

Michael D Jain (Michael Jain)